{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:44:26Z","timestamp":1782477866456,"version":"3.54.5"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T00:00:00Z","timestamp":1530489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41401-018-0059-x","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T09:20:24Z","timestamp":1530523224000},"page":"365-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats"],"prefix":"10.1038","volume":"40","author":[{"given":"Xiang-hu","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe J.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Vemuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-hua","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot L.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Makriyannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-xiong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,2]]},"reference":[{"key":"59_CR1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1360-0443.2012.03993.x","volume":"108","author":"JE Brady","year":"2013","unstructured":"Brady JE, Li G. Prevalence of alcohol and other drugs in fatally injured drivers. Addiction. 2013;108:104\u201314.","journal-title":"Addiction"},{"key":"59_CR2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/B978-0-444-53497-2.00049-8","volume":"116","author":"J Naim-Feil","year":"2013","unstructured":"Naim-Feil J, Zangen A. Addiction. Handb Clin Neurol. 2013;116:613\u201330.","journal-title":"Handb Clin Neurol"},{"key":"59_CR3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.drugalcdep.2014.08.004","volume":"143","author":"L Jing","year":"2014","unstructured":"Jing L, Qiu Y, Zhang Y, Li JX. Effects of the cannabinoid CB(1) receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats. Drug Alcohol Depend. 2014;143:251\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"59_CR4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/dta.1529","volume":"6","author":"PJ Robson","year":"2014","unstructured":"Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Test Anal. 2014;6:24\u201330.","journal-title":"Drug Test Anal"},{"key":"59_CR5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nn.2874","volume":"14","author":"ZX Xi","year":"2011","unstructured":"Xi ZX, Peng XQ,\u00a0Li X,\u00a0Song R,\u00a0Zhang HY,\u00a0Liu QR, et al. Brain cannabinoid CB(2) receptors modulate cocaine\u2019s actions in mice. Nat Neurosci. 2011;14:1160\u20136.","journal-title":"Nat Neurosci"},{"key":"59_CR6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1369-1600.2008.00109.x","volume":"13","author":"J Wiskerke","year":"2008","unstructured":"Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ. The role of CB1 receptors in psychostimulant addiction. Addict Biol. 2008;13:225\u201338.","journal-title":"Addict Biol"},{"key":"59_CR7","doi-asserted-by":"crossref","first-page":"E5007","DOI":"10.1073\/pnas.1413210111","volume":"111","author":"HY Zhang","year":"2014","unstructured":"Zhang HY, Gao M,\u00a0Liu QR,\u00a0Bi GH,\u00a0Li X,\u00a0Yang HJ, et al. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A. 2014;111:E5007\u201315.","journal-title":"Proc Natl Acad Sci USA"},{"key":"59_CR8","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","volume":"87","author":"M Herkenham","year":"1990","unstructured":"Herkenham M, Lynn AB,\u00a0Little MD,\u00a0Johnson MR,\u00a0Melvin LS,\u00a0de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87:1932\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"59_CR9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/0306-4522(92)90409-U","volume":"48","author":"P Mailleux","year":"1992","unstructured":"Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 1992;48:655\u201368.","journal-title":"Neuroscience"},{"key":"59_CR10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0014-2999(90)94136-L","volume":"190","author":"J Chen","year":"1990","unstructured":"Chen J, Paredes W, Lowinson JH, Gardner EL. Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol. 1990;190:259\u201362.","journal-title":"Eur J Pharmacol"},{"key":"59_CR11","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1126\/science.276.5321.2048","volume":"276","author":"G Tanda","year":"1997","unstructured":"Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997;276:2048\u201350.","journal-title":"Science"},{"key":"59_CR12","doi-asserted-by":"crossref","first-page":"pii:a012229","DOI":"10.1101\/cshperspect.a012229","volume":"2","author":"EB Oleson","year":"2012","unstructured":"Oleson EB, Cheer JF. A brain on cannabinoids: the role of dopamine release in reward seeking. Cold Spring Harb Perspect Med. 2012;2: pii:a012229.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"59_CR13","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.neuropharm.2005.03.016","volume":"48","author":"CR Lupica","year":"2005","unstructured":"Lupica CR, Riegel AC. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology. 2005;48:1105\u201316.","journal-title":"Neuropharmacology"},{"key":"59_CR14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-009-1506-7","volume":"205","author":"B Foll Le","year":"2009","unstructured":"Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology. 2009;205:171\u20134.","journal-title":"Psychopharmacology"},{"key":"59_CR15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fpsyt.2015.00041","volume":"6","author":"IH Gamaleddin","year":"2015","unstructured":"Gamaleddin IH, Trigo JM,\u00a0Gueye AB,\u00a0Zvonok A,\u00a0Makriyannis A,\u00a0Goldberg SR, et al. Role of the endogenous cannabinoid system in nicotine addiction: novel insights. Front Psychiatry. 2015;6:41.","journal-title":"Front Psychiatry"},{"key":"59_CR16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.104.077974","volume":"312","author":"B Foll Le","year":"2005","unstructured":"Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther. 2005;312:875\u201383.","journal-title":"J Pharmacol Exp Ther"},{"key":"59_CR17","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.npp.1301552","volume":"33","author":"ZX Xi","year":"2008","unstructured":"Xi ZX, Spiller K,\u00a0Pak AC,\u00a0Gilbert J,\u00a0Dillon C,\u00a0Li X,\u00a0et al. Cannabinoid CB1 receptor antagonists attenuate cocaine\u2019s rewarding effects: experiments with self-administration and brain-stimulation reward in rats. Neuropsychopharmacology. 2008;33:1735\u201345.","journal-title":"Neuropsychopharmacology"},{"key":"59_CR18","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1523\/JNEUROSCI.21-14-05344.2001","volume":"21","author":"M Navarro","year":"2001","unstructured":"Navarro M, Carrera MR,\u00a0Fratta W,\u00a0Valverde O,\u00a0Cossu G,\u00a0Fattore L, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci. 2001;21:5344\u201350.","journal-title":"J Neurosci"},{"key":"59_CR19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/sj.npp.1300848","volume":"31","author":"S Caille","year":"2006","unstructured":"Caille S, Parsons LH. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology. 2006;31:804\u201313.","journal-title":"Neuropsychopharmacology"},{"key":"59_CR20","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1111\/j.1460-9568.2003.02961.x","volume":"18","author":"S Caille","year":"2003","unstructured":"Caille S, Parsons LH. SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci. 2003;18:3145\u20139.","journal-title":"Eur J Neurosci"},{"key":"59_CR21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejphar.2004.08.022","volume":"501","author":"M Navarro","year":"2004","unstructured":"Navarro M, Carrera MR,\u00a0Del Arco I,\u00a0Trigo JM,\u00a0Koob GF,\u00a0Rodr\u00edguez de Fonseca F.\u00a0Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats. Eur J Pharmacol. 2004;501:235\u20137.","journal-title":"Eur J Pharmacol"},{"key":"59_CR22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2010.02.005","volume":"633","author":"CW Schindler","year":"2010","unstructured":"Schindler CW, Panlilio LV,\u00a0Gilman JP,\u00a0Justinova Z,\u00a0Vemuri VK,\u00a0Makriyannis A, et al. Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys. Eur J Pharmacol. 2010;633:44\u20139.","journal-title":"Eur J Pharmacol"},{"key":"59_CR23","doi-asserted-by":"crossref","unstructured":"Cahill K, Ussher MH. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev. 2011;16:CD005353.","DOI":"10.1002\/14651858.CD005353.pub4"},{"key":"59_CR24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00213-003-1422-1","volume":"168","author":"TJ Vries De","year":"2003","unstructured":"De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology. 2003;168:164\u20139.","journal-title":"Psychopharmacology"},{"key":"59_CR25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s002130050518","volume":"135","author":"F Chaperon","year":"1998","unstructured":"Chaperon F, Soubrie P, Puech AJ, Thiebot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology. 1998;135:324\u201332.","journal-title":"Psychopharmacology"},{"key":"59_CR26","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nm1001-1151","volume":"7","author":"TJ Vries De","year":"2001","unstructured":"De Vries TJ, Shaham Y,\u00a0Homberg JR,\u00a0Crombag H,\u00a0Schuurman K,\u00a0Dieben J, et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med. 2001;7:1151\u20134.","journal-title":"Nat Med"},{"key":"59_CR27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.drugalcdep.2009.07.002","volume":"105","author":"SJ Ward","year":"2009","unstructured":"Ward SJ, Rosenberg M, Dykstra LA, Walker EA. The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse. Drug Alcohol Depend. 2009;105:248\u201355.","journal-title":"Drug Alcohol Depend"},{"key":"59_CR28","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1016\/j.lfs.2005.04.017","volume":"77","author":"MA Carai","year":"2005","unstructured":"Carai MA, Colombo G, Gessa GL. Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci. 2005;77:2339\u201350.","journal-title":"Life Sci"},{"key":"59_CR29","doi-asserted-by":"crossref","first-page":"H533","DOI":"10.1152\/ajpheart.00107.2005","volume":"289","author":"P Pacher","year":"2005","unstructured":"Pacher P, B\u00e1tkai S,\u00a0Osei-Hyiaman D,\u00a0Offert\u00e1ler L,\u00a0Liu J,\u00a0Harvey-White J, et al. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol. 2005;289:H533\u201341.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"59_CR30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1360-0443.2008.02454.x","volume":"104","author":"NA Rigotti","year":"2009","unstructured":"Rigotti NA, Gonzales D,\u00a0Dale LC,\u00a0Lawrence D,\u00a0Chang Y. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction. 2009;104:266\u201376.","journal-title":"Addiction"},{"key":"59_CR31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(07)60033-6","volume":"369","author":"RS Padwal","year":"2007","unstructured":"Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71\u20137.","journal-title":"Lancet"},{"key":"59_CR32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1734-1140(09)70025-8","volume":"61","author":"CE Leite","year":"2009","unstructured":"Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep. 2009;61:217\u201324.","journal-title":"Pharmacol Rep"},{"key":"59_CR33","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"LF Gaal Van","year":"2005","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, R\u00f6ssner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389\u201397.","journal-title":"Lancet"},{"key":"59_CR34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"FX Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761\u201375.","journal-title":"J Am Med Assoc"},{"key":"59_CR35","doi-asserted-by":"crossref","first-page":"R2185","DOI":"10.1152\/ajpregu.00663.2007","volume":"293","author":"AP Chambers","year":"2007","unstructured":"Chambers AP, Vemuri VK,\u00a0Peng Y,\u00a0Wood JT,\u00a0Olszewska T,\u00a0Pittman QJ, et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol. 2007;293:R2185\u201393.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"59_CR36","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ijo.2010.38","volume":"34","author":"J Proietto","year":"2010","unstructured":"Proietto J, Rissanen A,\u00a0Harp JB,\u00a0Erondu N,\u00a0Yu Q, Suryawanshi S, et al. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int J Obes (Lond). 2010;34:1243\u201354.","journal-title":"Int J Obes"},{"key":"59_CR37","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/sj.npp.1301476","volume":"33","author":"KS Sink","year":"2008","unstructured":"Sink KS, McLaughlin PJ,\u00a0Wood JA,\u00a0Brown C,\u00a0Fan P,\u00a0Vemuri VK,\u00a0et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology. 2008;33:946\u201355.","journal-title":"Neuropsychopharmacology"},{"key":"59_CR38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.pbb.2008.07.013","volume":"91","author":"KS Sink","year":"2009","unstructured":"Sink KS, Vemuri VK, Wood J, Makriyannis A, Salamone JD. Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav. 2009;91:303\u20136.","journal-title":"Pharmacol Biochem Behav"},{"key":"59_CR39","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1124\/jpet.103.049924","volume":"306","author":"S Ruiu","year":"2003","unstructured":"Ruiu S, Pinna GA,\u00a0Marchese G,\u00a0Mussinu JM,\u00a0Saba P,\u00a0Tambaro S, et al. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther. 2003;306:363\u201370.","journal-title":"J Pharmacol Exp Ther"},{"key":"59_CR40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/bs.mie.2017.06.025","volume":"593","author":"HH Seltzman","year":"2017","unstructured":"Seltzman HH, Maitra R, Bortoff K, Henson J, Reggio PH, Wesley D,\u00a0et al. Metabolic profiling of CB1 neutral antagonists. Methods Enzymol. 2017;593:199\u2013215.","journal-title":"Methods Enzymol"},{"key":"59_CR41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.neuropharm.2006.03.029","volume":"51","author":"FJ Pavon","year":"2006","unstructured":"Pavon FJ, \u00a0Bilbao A, Hern\u00e1ndez-Folgado L, Cippitelli A, Jagerovic N, Abell\u00e1n G, et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21. Neuropharmacology. 2006;51:358\u201366.","journal-title":"Neuropharmacology"},{"key":"59_CR42","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pbb.2008.06.014","volume":"91","author":"TU Jarbe","year":"2008","unstructured":"J\u00e4rbe TU,\u00a0LeMay BJ,\u00a0Olszewska T,\u00a0Vemuri VK,\u00a0Wood JT,\u00a0Makriyannis A. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharmacol Biochem Behav. 2008;91:84\u201390.","journal-title":"Pharmacol Biochem Behav"},{"key":"59_CR43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/jpet.112.201962","volume":"344","author":"BD Kangas","year":"2013","unstructured":"Kangas BD, Delatte MS,\u00a0Vemuri VK,\u00a0Thakur GA,\u00a0Nikas SP,\u00a0Subramanian KV,\u00a0et al. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther. 2013;344:561\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"59_CR44","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1007\/s00213-014-3575-5","volume":"231","author":"KL Wills","year":"2014","unstructured":"Wills KL, Vemuri K,\u00a0Kalmar A,\u00a0Lee A,\u00a0Limebeer CL,\u00a0Makriyannis A,\u00a0et al. CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats. Psychopharmacology. 2014;231:4291\u2013300.","journal-title":"Psychopharmacology"},{"key":"59_CR45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.10.040","volume":"131","author":"A Balla","year":"2017","unstructured":"Balla A, Dong B,\u00a0Shilpa BM,\u00a0Vemuri K,\u00a0Makriyannis A,\u00a0Pandey SC,\u00a0et al. Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling. Neuropharmacology. 2017;131:200\u20138.","journal-title":"Neuropharmacology"},{"key":"59_CR46","doi-asserted-by":"crossref","first-page":"pii:pyw068","DOI":"10.1093\/ijnp\/pyw068","volume":"19","author":"AB Gueye","year":"2016","unstructured":"Gueye AB, Pryslawsky Y,\u00a0Trigo JM,\u00a0Poulia N,\u00a0Delis F,\u00a0Antoniou K, et al. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. Int J Neuropsychopharmacol. 2016;19:pii:pyw068.","journal-title":"Int J Neuropsychopharmacol"},{"key":"59_CR47","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/npp.2016.27","volume":"41","author":"CW Schindler","year":"2016","unstructured":"Schindler CW, Redhi GH, Vemuri K, Makriyannis A, Le Foll B, Bergman J,\u00a0et al. Blockade of nicotine and cannabinoid reinforcement and relapse by a cannabinoid CB1-receptor neutral antagonist AM4113 and inverse agonist rimonabant in squirrel monkeys. Neuropsychopharmacology. 2016;41:2283\u201393.","journal-title":"Neuropsychopharmacology"},{"key":"59_CR48","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","volume":"36","author":"A Kolodny","year":"2015","unstructured":"Kolodny A, Courtwright DT,\u00a0Hwang CS,\u00a0Kreiner P,\u00a0Eadie JL,\u00a0Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559\u201374.","journal-title":"Annu Rev Public Health"},{"key":"59_CR49","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/mp.2011.46","volume":"16","author":"PW Kalivas","year":"2011","unstructured":"Kalivas PW, Volkow ND. New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry. 2011;16:974\u201386.","journal-title":"Mol Psychiatry"},{"key":"59_CR50","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2982.2010.01478.x","volume":"22","author":"MA Storr","year":"2010","unstructured":"Storr MA, Bashashati M,\u00a0Hirota C,\u00a0Vemuri VK,\u00a0Keenan CM,\u00a0Duncan M, et al. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil. 2010;22:787\u201396, e223.","journal-title":"Neurogastroenterol Motil"},{"key":"59_CR51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pbb.2005.01.032","volume":"81","author":"EL Gardner","year":"2005","unstructured":"Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav. 2005;81:263\u201384.","journal-title":"Pharmacol Biochem Behav"},{"key":"59_CR52","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1523\/JNEUROSCI.0726-06.2006","volume":"26","author":"ZX Xi","year":"2006","unstructured":"Xi ZX, Gilbert JG,\u00a0Peng XQ,\u00a0Pak AC,\u00a0Li X,\u00a0Gardner EL. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. J Neurosci. 2006;26:8531\u20136.","journal-title":"J Neurosci"},{"key":"59_CR53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2005.06.018","volume":"108","author":"CP O\u2019Brien","year":"2005","unstructured":"O\u2019Brien CP, Gardner EL. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther. 2005;108:18\u201358.","journal-title":"Pharmacol Ther"},{"key":"59_CR54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1124\/jpet.102.047928","volume":"306","author":"M Solinas","year":"2003","unstructured":"Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther. 2003;306:93\u2013102.","journal-title":"J Pharmacol Exp Ther"},{"key":"59_CR55","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.neuropharm.2005.01.022","volume":"48","author":"L Fattore","year":"2005","unstructured":"Fattore L, Spano S,\u00a0Cossu G,\u00a0Deiana S,\u00a0Fadda P,\u00a0Fratta W. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology. 2005;48:1097\u2013104.","journal-title":"Neuropharmacology"},{"key":"59_CR56","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/sj.npp.1301630","volume":"33","author":"L Alvarez-Jaimes","year":"2008","unstructured":"Alvarez-Jaimes L, Polis I, Parsons LH. Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala. Neuropsychopharmacology. 2008;33:2483\u201393.","journal-title":"Neuropsychopharmacology"},{"key":"59_CR57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pbb.2005.01.024","volume":"81","author":"C Cohen","year":"2005","unstructured":"Cohen C, Kodas E, Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav. 2005;81:387\u201395.","journal-title":"Pharmacol Biochem Behav"},{"key":"59_CR58","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.neuropharm.2007.10.011","volume":"54","author":"M Shoaib","year":"2008","unstructured":"Shoaib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology. 2008;54:438\u201344.","journal-title":"Neuropharmacology"},{"key":"59_CR59","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1734-1140(09)70036-2","volume":"61","author":"B Budzynska","year":"2009","unstructured":"Budzynska B, Kruk M, Biala G. Effects of the cannabinoid CB1 receptor antagonist AM 251 on the reinstatement of nicotine-conditioned place preference by drug priming in rats. Pharmacol Rep. 2009;61:304\u201310.","journal-title":"Pharmacol Rep"},{"key":"59_CR60","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1369-1600.2012.00476.x","volume":"18","author":"A Simonnet","year":"2013","unstructured":"Simonnet A, Cador M, Caille S. Nicotine reinforcement is reduced by cannabinoid CB1 receptor blockade in the ventral tegmental area. Addict Biol. 2013;18:930\u20136.","journal-title":"Addict Biol"},{"key":"59_CR61","first-page":"806","volume":"58","author":"M Filip","year":"2006","unstructured":"Filip M, Go\u0142da A,\u00a0Zaniewska M,\u00a0McCreary AC,\u00a0Nowak E,\u00a0Kolasiewicz W, et al. Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine. Pharmacol Rep. 2006;58:806\u201319.","journal-title":"Pharmacol Rep"},{"key":"59_CR62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euroneuro.2004.04.003","volume":"15","author":"HM Lesscher","year":"2005","unstructured":"Lesscher HM, Hoogveld E, Burbach JP, van Ree JM, Gerrits MA. Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. Eur Neuropsychopharmacol. 2005;15:31\u20137.","journal-title":"Eur Neuropsychopharmacol"},{"key":"59_CR63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/026988110201600204","volume":"16","author":"J Vinklerova","year":"2002","unstructured":"Vinklerova J, Novakova J, Sulcova A. Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. J Psychopharmacol. 2002;16:139\u201343.","journal-title":"J Psychopharmacol"},{"key":"59_CR64","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/sj.npp.1300454","volume":"29","author":"K Anggadiredja","year":"2004","unstructured":"Anggadiredja K, akamichi M,\u00a0Hiranita T,\u00a0Tanaka H,\u00a0Shoyama Y,\u00a0Watanabe S, et al. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology. 2004;29:1470\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"59_CR65","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.neuropharm.2008.08.012","volume":"55","author":"T Hiranita","year":"2008","unstructured":"Hiranita T, Nawata Y, Sakimura K, Yamamoto T. Methamphetamine-seeking behavior is due to inhibition of nicotinic cholinergic transmission by activation of cannabinoid CB1 receptors. Neuropharmacology. 2008;55:1300\u20136.","journal-title":"Neuropharmacology"},{"key":"59_CR66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2007.06.004","volume":"571","author":"SY Boctor","year":"2007","unstructured":"Boctor SY, Martinez JL Jr., Koek W, France CP. The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding. Eur J Pharmacol. 2007;571:39\u201343.","journal-title":"Eur J Pharmacol"},{"key":"59_CR67","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.ne.19.030196.001535","volume":"19","author":"RA Wise","year":"1996","unstructured":"Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci. 1996;19:319\u201340.","journal-title":"Annu Rev Neurosci"},{"key":"59_CR68","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1530-0277.2009.01069.x","volume":"34","author":"EW Fish","year":"2010","unstructured":"Fish EW, Riday TT,\u00a0McGuigan MM,\u00a0Faccidomo S,\u00a0Hodge CW,\u00a0Malanga CJ.\u00a0Alcohol, cocaine, and brain stimulation-reward in C57Bl6\/J and DBA2\/J mice. Alcohol Clin Exp Res. 2010;34:81\u20139.","journal-title":"Alcohol Clin Exp Res"},{"key":"59_CR69","unstructured":"Paxinos G & Watson C (1998) The Rat Brain in Stereotaxic Coordinates. Academic Press."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0059-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0059-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0059-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:01:09Z","timestamp":1684616469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-018-0059-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,2]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["59"],"URL":"https:\/\/doi.org\/10.1038\/s41401-018-0059-x","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,2]]},"assertion":[{"value":"21 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}